RxDoctor Payments DataLook up a doctor →

Brett Dees, MD

Neurology · Norman, OKNPI 1770789075

Payments from drug & device makers

$618,182in general payments, 2019–2025

Across 1,273 payments — averaging $485.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$216K
  • Biohaven Pharmaceutical Holding Company Ltd.$110K
  • Biohaven Pharmaceuticals, Inc.$73K
  • Pfizer$67K
  • Lilly USA, LLC$63K
  • Amgen$51K
  • plus $38K from 37 others
$48,675in research payments, 2019–2025

Across 7 payments — averaging $6953.63 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$49K

What the payments were for

  • Consulting fees$24,3696%
  • Speaking & faculty fees$367,59587%
  • Travel & lodging$10,5713%
  • Food & beverage$17,9054%
  • Education$420%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$618,182 in reported general payments places this provider in the 90th percentile of 152 neurology providers in Oklahoma.

See all neurology providers in Oklahoma

Medicare billing

Part B allowed, 2024
$199,193
Medicare patients
246
Services billed
20,401

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UbrelvyUbrogepant148$208,323
Nurtec OdtRimegepant Sulfate98$155,100
Aimovig AutoinjectorErenumab-Aooe157$115,532
AustedoDeutetrabenazine16$98,888
QuliptaAtogepant77$93,974
Emgality PenGalcanezumab-Gnlm66$54,310
BotoxOnabotulinumtoxina41$53,167
ReyvowLasmiditan Succinate32$29,683
Ajovy AutoinjectorFremanezumab-Vfrm30$24,045
Ajovy SyringeFremanezumab-Vfrm12$10,035
BelsomraSuvorexant17$9,189
Emgality SyringeGalcanezumab-Gnlm11$8,043
Trokendi XrTopiramate14$5,949
Sumatriptan Succinate37$5,755
Candesartan Cilexetil51$4,521

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta, Botox$215,965$355,465266 claims
PfizerNurtec Odt$66,971$155,10098 claims
Teva Pharmaceuticals USA, Inc.Austedo$614$98,88816 claims
Lilly USA, LLCReyvow$62,962$29,68332 claims
MerckBelsomra$16$9,18917 claims
Supernus Pharmaceuticals, Inc.Trokendi Xr$309$5,94914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 152 neurology providers in Oklahoma.

Other neurology in Norman

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →